Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

Lytix Biopharma AS. (3/1/16). "Press Release: Håkan Wickholm New CEO, Acting, in Lytix Biopharma".

Organisation Organisation Lytix Biopharma AS
Products Product LTX-315 (Lytix Biopharma)
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Wickholm, Håkan (Lytix Biopharma AS 201603– CEO)
  Person 2 Hjelmaas, Unni (Lytix Biopharma 2012–201602 CEO)

Effective March 1st Håkan Wickholm has succeeded Unni Hjelmaas as CEO in Lytix Biopharma.

Mr. Wickholm’s appointment reflects the new phase in Lytix Biopharma’s development with increasing focus on Business Development. Håkan Wickholm will continue as head of Business Development.

Board Chair Gert W. Munthe says:
“The entire Board is delighted that Håkan Wickholm now takes on this role as the clinical program is starting to show substantial immune responses in patients treated with LTX-315. This lays the foundation for successful business development activities. At the same time the Board would like to express their thanks to Unni Hjelmaas for her hard work and dedication to Lytix Biopharma in her four years as CEO.”

Håkan Wickholm says:
“I am very excited by this opportunity to take on the role of CEO at this stage, when important immune response data develops, allowing us to intensify business development activities and further clinical development. ’’

Further information:

Håkan Wickholm (CEO)
Tel (+46) 727 172 526, e-mail:
Gert W. Munthe, Chairman of the Board
Tel (+47) 920 22 363, e-mail:

Lytix Biopharma’s technology is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to end Phase II, and then collaborate with partners for the final stages of product development and commercialization.

Record changed: 2016-03-01


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Lytix Biopharma AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top